Core Insights - Yantai's biopharmaceutical industry has reached a scale of 212 regulated enterprises, with a cumulative launch of 6 class 1 new drugs in recent years, indicating significant growth in the sector [1][3][4] Group 1: Industry Development - The "Blue Pharmaceutical Valley" in Yantai has become a core area for the biopharmaceutical industry, with a total investment of 12 billion yuan and a construction area of 1.3 million square meters, attracting 34 biopharmaceutical companies [2][3] - Yantai's biopharmaceutical industry has achieved over 100 billion yuan in annual revenue for several consecutive years, establishing itself as a key player in China's biopharmaceutical landscape [3][4] - The city has implemented a "chain leader system" to enhance the biopharmaceutical industry, focusing on extending the industrial chain, improving the value chain, and integrating the supply chain [3][4] Group 2: Innovation and Infrastructure - Yantai has established a comprehensive vertical ecosystem for the biopharmaceutical industry, covering product research and development, results transformation, inspection and approval, and production and sales [4][5] - The city has launched 6 class 1 new drugs in recent years, leading the province, and aims to average 1-2 new class 1 drugs annually over the next five years [4][5] - The "Blue Pharmaceutical Valley" has the largest area in China for nuclear medicine production environmental assessment qualifications, with 12 class 1 nuclear drugs currently in clinical trials [5][6] Group 3: Strategic Focus Areas - Yantai is focusing on two key areas: medical isotopes and radioactive drugs, as well as cell and gene therapy, while also nurturing growth in innovative drugs, high-end generics, high-end medical devices, and traditional Chinese medicine [5][6] - The city has invested 297 million yuan to establish a top-tier cell product pilot platform, significantly reducing the landing costs for enterprises and attracting more cell drug companies [5][6]